Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Aug 2, 2012)
  • 8-K (Jul 30, 2012)
  • 8-K (Jul 27, 2012)
  • 8-K (Jul 26, 2012)
  • 8-K (Jun 18, 2012)
  • 8-K (Jun 15, 2012)

 
Other

Genta 8-K 2012

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Graphic
  4. Graphic
genta_8k-052212.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
 


FORM 8-K
 
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
 
Date of report (Date of earliest event reported):  May 22, 2012
 
GENTA INCORPORATED
(Exact Name of Registrant
as Specified in Its Charter)
 
 
Delaware
 
 
(State or Other Jurisdiction of Incorporation)
 
 
0-19635
 
33-0326866
(Commission File Number)
 
(IRS Employer Identification No.)
 
200 Connell Drive
Berkeley Heights, NJ
 
07922
(Address of Principal Executive Offices)
 
(Zip Code)
 
 
(908) 286-9800
 
(Registrant’s Telephone Number, Including Area Code)
 
(Former Name or Former Address, if Changed Since Last Report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant
under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

o Pre -commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

o Pre -commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
 

 
 
Item 8.01 Other Events.

On May 22, 2012, Genta Incorporated  announced results from the Company’s Phase 2 clinical trial using tesetaxel as initial, single-agent chemotherapy in women with advanced breast cancer.  The data will be formally presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.  Tesetaxel is the leading oral taxane in clinical development.  The trial is lead by Memorial Sloan-Kettering Cancer Center, New York, NY, in collaboration with three other U.S. centers.

Women were eligible if they had not received chemotherapy for locally advanced or metastatic HER2-negative breast cancer.  Prior adjuvant chemotherapy was allowed if the recurrence was at least 12 months from the last dose.  Forty-six patients were accrued to the trial, and 44 are currently evaluable for response.  Seventy percent of patients had received adjuvant chemotherapy; more than 80% of those regimens had included an injectable taxane.  More than 50% of patients had received local radiotherapy, and approximately two-thirds had progressed on one or more hormonal therapies.

Major objective responses were observed in 20 of 44 patients (45%), including 1 complete response and 19 partial responses.  Seven of the major responders cleared more than 75% of their measurable disease.  The disease-control/clinical-benefit rate, which includes major responders and patients with stable disease, was 82%.

Exploratory analyses showed that 17 of 35 patients (49%) whose disease was estrogen receptor positive (ER+) had major responses.  Median progression-free survival in the ER+ population was 7.3 months.  In women with “triple-negative” disease, which is relatively insensitive to chemotherapy, 3 of 9 patients responded (33%).

Tesetaxel was generally well-tolerated.  Neutropenia was the most common Grade 3-4 adverse event.  The incidence of Grade 4 neutropenia was sharply reduced (from 32% to 11%) after dose escalation (from the starting level of 27 mg/m2 to 35 mg/m2) was discontinued – a change that has now been incorporated into all protocols.  Consistent with prior studies, no hypersensitivity reactions were observed.

“These data confirm results from our prior study, both of which show substantial activity for tesetaxel in patients with advanced, HER2-negative breast cancer”, said Dr. Loretta M. Itri, Genta’s President, Pharmaceutical Development, and Chief Medical Officer.  “Genta is also exploring an alternate dosing schedule in this population using weekly treatment.  Based on this favorable experience, and after conferring with regulatory authorities in the U.S. and EU, Genta plans to proceed with a new randomized trial of tesetaxel as initial, single-agent chemotherapy for patients with recurrent breast cancer.”

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 
Exhibit
Number
 
 
Description
 
 
99.1
 
Press Release of the Company dated May 22, 2012
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
   
GENTA INCORPORATED
     
Date:
May 22, 2012
 
By:
/s/ GARY SIEGEL
       
Name:
Gary Siegel
       
Title:
Vice President, Finance

 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki